Open11.410 | Close11.220 |
Vol / Avg.2.810M / 2.501M | Mkt Cap3.290B |
Day Range11.190 - 11.480 | 52 Wk Range9.700 - 14.100 |
Amicus Therapeutics Stock (NASDAQ: FOLD) stock price, news, charts, stock research, profile.
Open11.410 | Close11.220 |
Vol / Avg.2.810M / 2.501M | Mkt Cap3.290B |
Day Range11.190 - 11.480 | 52 Wk Range9.700 - 14.100 |
Q4 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.080 | -0.070 | 0.0100 | ||||
REV | 101.360M | 103.501M | 2.141M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-11-09 | Morgan Stanley | Andrew Galler | Maintains | Equal-WeightEqual-Weight | Raises | 14.00 | 15.00 |
2023-10-10 | Morgan Stanley | Andrew Galler | Maintains | Equal-WeightEqual-Weight | Lowers | 15.00 | 14.00 |
2023-09-29 | JP Morgan | Anupam Rama | Maintains | OverweightOverweight | Raises | 17.00 | 19.00 |
2023-07-11 | Morgan Stanley | Andrew Galler | Reiterates | Equal-WeightEqual-Weight | Maintains | 15.00 | 15.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
FOLD | Amicus Therapeutics | -2.18% | 3.3B |
RARE | Ultragenyx Pharmaceutical | -2.32% | 3.3B |
MLTX | MoonLake | 2.39% | 3.4B |
ALKS | Alkermes | -1.15% | 4.3B |
MRTX | Mirati Therapeutics | -0.35% | 4B |
You can purchase shares of Amicus Therapeutics (NASDAQ: FOLD) through any online brokerage.
Other companies in Amicus Therapeutics’s space includes: Ultragenyx Pharmaceutical (NASDAQ:RARE), MoonLake (NASDAQ:MLTX), Alkermes (NASDAQ:ALKS), Mirati Therapeutics (NASDAQ:MRTX) and Vaxcyte (NASDAQ:PCVX).
The latest price target for Amicus Therapeutics (NASDAQ: FOLD) was reported by Morgan Stanley on Thursday, November 9, 2023. The analyst firm set a price target for 15.00 expecting FOLD to rise to within 12 months (a possible 33.69% upside). 8 analyst firms have reported ratings in the last year.
The stock price for Amicus Therapeutics (NASDAQ: FOLD) is $11.22 last updated December 8, 2023 at 9:20 PM UTC.
There is no dividend information for Amicus Therapeutics.
Amicus Therapeutics’s Q4 earnings are confirmed for Wednesday, February 28, 2024.
There is no upcoming split for Amicus Therapeutics.
Amicus Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.